Skip to content
Clinical Trials – home
GermanyBack to Germany

Clinical trials in Biberach – page 38

668 clinical trials in Biberach, Germany across 1 research site. Every trial is listed in the EU Clinical Trials Register and updated daily.

GermanyOur site in GermanyKlinischeStudien.de(opens in a new tab)
Biberach at a glance
668
clinical trials
  • Research sites1
Type of trial
Recruitment status
Quick filters

668 trials in Biberach

Open in trial search

Study on Tolebrutinib for Patients with Primary Progressive Multiple Sclerosis

Investigational
Countries:GermanyGermany
  • Participants:18–64 years
  • Substances:Tolebrutinib
  • Sponsor:Genzyme Corp.

Crohn's disease

Not recruiting

Study on BI 706321 and Ustekinumab for Patients with Moderate to Severe Crohn's Disease

Registered drug
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:BI 706321
  • Sponsor:Boehringer Ingelheim International GmbH

Study on Fenebrutinib and Teriflunomide for Adults with Relapsing Multiple Sclerosis

Registered drug
Countries:GermanyGermany
  • Participants:18–64 years
  • Substances:Fenebrutinib
  • Sponsor:F. Hoffmann-La Roche AG

Study on MaaT013 for Treating Acute Gastrointestinal Graft-Versus-Host Disease in Patients Not Responding to Ruxolitinib

InvestigationalNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Allogeneic Faecal Microbiota, Pooled
  • Sponsor:Maat Pharma

Study on the Safety and Effectiveness of Ivosidenib or Enasidenib with Azacitidine for Patients with Newly Diagnosed Acute Myeloid Leukemia with IDH1 or IDH2 Mutations

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Azacitidine
  • Sponsor:Celgene Corp.

Study on Long-Term Safety and Effectiveness of Ofatumumab for Patients with Relapsing Multiple Sclerosis

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years
  • Substances:Ofatumumab
  • Sponsor:Novartis Pharma AG

Study of Belimumab with Rituximab and Venetoclax for Patients with Refractory or Relapsed Chronic Lymphocytic Leukemia

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Belimumab
  • Sponsor:Universitaetsklinikum Tuebingen AöR

IgA nephropathy

Not recruiting

Study on the Effectiveness and Safety of Iptacopan for Patients with Primary IgA Nephropathy

Investigational
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Iptacopan
  • Sponsor:Novartis Pharma AG

Plasma cell myeloma

Not recruiting

Study on Adding Isatuximab to Lenalidomide, Bortezomib, and Dexamethasone for Patients with Newly Diagnosed Multiple Myeloma

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Bortezomib
  • Sponsor:Universitaetsklinikum Heidelberg AöR

Acute myeloid leukaemia+1

Not recruiting

Study Comparing Gilteritinib and Midostaurin with Chemotherapy for Newly Diagnosed Acute Myeloid Leukemia or Myelodysplastic Syndrome with FLT3 Mutation

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Gilteritinib
  • Sponsor:Hemato-Oncologie voor Volwassenen Nederland (Hovon) Stichting

Study on ABBV-400 with Fluorouracil, Folinic Acid, and Bevacizumab for Adults with Unresectable Metastatic Colorectal Cancer

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Bevacizumab
  • Sponsor:AbbVie Deutschland GmbH & Co. KG

Migraine

Not recruiting

Study on Rimegepant for Preventing Migraines in Adults with Poor Response to Oral Preventive Medications

Registered drug
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Rimegepant
  • Sponsor:Pfizer Inc.

Other cities in Germany

The busiest research cities in the country

All 503 cities in Germany

Clinical research in Biberach

What the registry says about research in the country

01 Eye Diseases and Related Research

In Biberach An Der Riss, much of the clinical trial activity is connected to eye diseases and broader investigational research in healthy volunteers. The studies are focused on understanding how new treatments are absorbed, how food affects them, and how they interact with other medicines.

  • Research involving Eye Diseases and unspecified disease areas
  • Studies in healthy volunteers and otherwise healthy participants
  • Trials exploring pharmacokinetics and medicine interactions
  • Work aimed at improving treatment use and safety for future care

These trials help clarify how candidate therapies behave in the body and support the development of better treatment options.

02 Pharmacokinetic Studies

A major part of the research landscape centers on pharmacokinetic trial work, especially in healthy people. These studies are designed to see how medicines are absorbed, distributed, and influenced by food or other drugs.

  • Testing how different formulations are taken up in the body
  • Checking the effect of food on medicine exposure
  • Evaluating possible drug-drug interactions
  • Supporting the safe development of new oral therapies

The goal is to build a clearer picture of how investigational medicines behave before wider clinical use.

03 Healthy Volunteer Trials

Many of the studies in this city involve healthy volunteer trial designs, which are used to test safety, tolerability, and how the body responds to new compounds. This research is essential for early evaluation of promising medicines.

  • Assessing how well new treatments are tolerated
  • Comparing tablet and injection-style formulations
  • Measuring exposure changes with common co-medications
  • Generating data that supports further clinical development

The emphasis is on careful observation of how healthy participants respond to study medicines.

04 Metabolic and Cardiovascular Research

Some trials also address broader metabolic and cardiovascular interests, including medicines studied for body weight-related conditions and heart effects. These projects aim to understand both benefit and safety across different formulations.

  • Research on therapies related to obesity and metabolism
  • Studies of heart-related effects and medicine exposure
  • Comparisons of separate versus combined medicine use
  • Support for better treatment planning in chronic disease care

This area reflects a wider effort to refine new treatments for complex health conditions.

Clinical Trials Concierge

Prefer not to search on your own, or looking for clinical trials for a rare disease?

Tell us about your condition – we search every trial in Europe and connect you with the right site.